Biote corp.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical ...Biote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III Biote is a high-growth medical practice-building company operating within the multi-billion dollar ...biote Corp. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 (312) 212-8079 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Ryan Sansom Peter Byrne Cooley LLP 500 Boylston Street Boston, MA 02116-3736 (617) 937-2300 Steven Burwell Proskauer Rose LLP 11 Times Square New York, NY 10036 ...biote Corp. Up to 72,069,990 Shares of Class A Common Stock . Up to 67,856,462 Shares of Class A Common Stock . Up to 5,566,666 Warrants. This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-265714), as amended. IRVING, Texas -- (BUSINESS WIRE)--Nov. 7, 2023-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of …
About Biote. Founded in 2012, Biote has experience phenomenal growth over the last decade. The Biote state-of-the-art training facility hosts physicians, healthcare providers, and medical staff members monthly during the Biote Method learning and certification process. To date, more than 6,400 medical practitioners have successfully completed ... biote Corp. provides precision and preventive medicines. The Company offers hormone therapy and products that boosts energy and immune system. biote serves customers …Biote Corp. (NASDAQ:BTMD) experienced a notable decline in short interest during the month of August, according to recent reports. On August 31st, the total short interest reached 549,400 shares, showing a significant drop of 32.8% from the total on August 15th which stood at 817,700 shares.
IRVING, Texas--(BUSINESS WIRE)--Feb. 9, 2023-- Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market.Irving-based Biote, a medical practice-building business within the hormone optimization space, will be listed on Nasdaq through a business combination with Haymaker Acquisition Corp. III. Biote—which will earn projected revenue of $136 million in 2021—trains practitioners to identify and treat early indicators of hormone-related aging conditions.
biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support.biote Corp. Up to 72,069,990 Shares of Class A Common Stock . Up to 67,856,462 Shares of Class A Common Stock . Up to 5,566,666 Warrants. This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-265714), as amended. On March 4, 2021, HYAC completed its IPO. On the Closing Date, the Business Combination with Biote was consummated, resulting in the Combined Company being organized in an “Up-C” structure, and HYAC as the registrant changed its name to “biote Corp.” Biote’s headquarters is located at 1875 W. Walnut Hill Ln #100 Irving, Texas 75038. Biote to Present at Jefferies London Healthcare Conference. IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading ...
May 24, 2022 · NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) — Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker” or the “Company”), a publicly traded special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the “Business Combination”) with Biote, and the related ...
2023 Third Quarter Financial Review. Revenue for the third quarter of 2023 was $45.6 million, an increase of 8.5% from $42.0 million for the third quarter of 2022. The increase in revenue was driven by procedure revenue growth of 7.4% and dietary supplement revenue growth of 5.1%. As expected, third quarter dietary supplement revenue growth ...
First Quarter 2023 Financial Highlights, year-over-year: Revenue of $44.8 million, a 20.7% increase. Gross profit margin of 69.1%, a 220-basis point increase. Net loss of $ (21.4) million and GAAP loss per share of $ (0.39), primarily reflecting the impact of transaction-related items. Adjusted EBITDA of $13.1 million, a 12.4% increase 1.A certain stockholder of biote Corp., a Delaware corporation (the “Company”) named in Schedule II attached hereto (the “Selling Stockholder”), propose, subject to the terms and conditions herein, to sell 5,217,392 shares (the “Firm Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”).III, a $317.5 million SPAC which successfully completed a business transaction with biote Corp. Prior and current public company board experience: Director of ...biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and ...The Investor Relations website contains information about biote Corp's business for stockholders, potential investors, and financial analysts.
Biote Holdings is merging with blank-cheque firm Haymaker Acquisition in a $737m (£556.8m) transaction to take it public, the companies have announced. Haymaker Acquisition stock rose 0.70% to $10.70 from $10 per share after the market open but fell to $9.91 per share by noon EDT (UTC-5). Haymaker Acquisition trades over the Nasdaq …May 26, 2022 · IRVING, Texas-- ( BUSINESS WIRE )--biote Corp., (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization... biote Corp. provides precision and preventive medicines. The Company offers hormone therapy and products that boosts energy and immune system. biote serves customers …Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ... biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified ...biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified ...
IRVING, Texas--(BUSINESS WIRE)--Aug. 24, 2022-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer. Mr. Kamdar will oversee Biote's financial operations with a focus …
biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical ...2023 Third Quarter Financial Review. Revenue for the third quarter of 2023 was $45.6 million, an increase of 8.5% from $42.0 million for the third quarter of 2022. The increase in revenue was driven by procedure revenue growth of 7.4% and dietary supplement revenue growth of 5.1%. As expected, third quarter dietary supplement revenue growth ...biote Corp. Up to 72,069,990 Shares of Class A Common Stock . Up to 67,856,462 Shares of Class A Common Stock . Up to 5,566,666 Warrants . This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-265714), as amended.Description of Business—biote Corp. (inclusive of its consolidated subsidiaries, the “Company” or “Biote”) is a Delaware incorporated company headquartered in Irving, Texas. The Company was founded in 2012 and trains physicians and nurse practitioners in hormone optimization using bio-identical hormone replacement pellet …As previously disclosed, on May 9, 2023, biote Corp. (the “ Company ”), commenced (i) its offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), of the Company, at an exercise price of $11.50 per share (the “ …Nov 7, 2023 · biote Corp Stock Price History. biote Corp’s price is currently up 9.01% so far this month. During the month of November, biote Corp’s stock price has reached a high of $5.81 and a low of $5.28. Over the last year, biote Corp has hit prices as high as $8.22 and as low as $2.75. Year to date, biote Corp’s stock is down 40.71%. IRVING, Texas--(BUSINESS WIRE)--Apr. 26, 2023-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide first quarter financial results on Tuesday, May 9, 2023, after the close of the market.A …Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related. Audit Report or Completed Interim Review. (a) On March 24, 2023, the audit committee of the board of directors (the "Audit Committee") of biote Corp. (the "Company"), based on the recommendation of, and after consultation with, the Company's …biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements.
When starting a business, one of the most important decisions you’ll have to make is choosing the right legal structure. Limited Liability Companies (LLCs) and S Corporations (S Corps) are two popular options that offer liability protection...
Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 May. 09: CI Certain Restricted Stock Units of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023. Apr. 05: CI Certain Stock Options of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023.
On May 26, 2022, Haymaker completed the Business Combination with Biote and changed its name to “biote Corp.”. On May 26, 2022, the Company issued a press release announcing the consummation of the Business Combination. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.August 24, 2022 08:30 AM Eastern Daylight Time. IRVING, Texas-- ( BUSINESS WIRE )-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business ...biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize …On March 4, 2021, HYAC completed its IPO. On the Closing Date, the Business Combination with Biote was consummated, resulting in the Combined Company being organized in an “Up-C” structure, and HYAC as the registrant changed its name to “biote Corp.” Biote’s headquarters is located at 1875 W. Walnut Hill Ln #100 Irving, Texas 75038.Stock analysis for Biote Corp (BTMD:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Oct 10, 2022 · IRVING, Texas -- (BUSINESS WIRE)--Oct. 10, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today released a new Corporate Presentation, which the Company may use from time to time in communications with investors or ... As of November 22, 2023, biote Corp had a $371.1 million market capitalization, putting it in the 53rd percentile of companies in the Professional Information Services industry. biote Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. biote Corp’s trailing 12-month revenue is $184.1 million …A certain stockholder of biote Corp., a Delaware corporation (the “Company”) named in Schedule II attached hereto (the “Selling Stockholder”), propose, subject to the terms and conditions herein, to sell 5,217,392 shares (the “Firm Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”).BioTE® optimizes hormone levels with tiny pellets just under the skin. Hormone pellets release bio-identical hormones into the bloodstream continuously. After ...Conference Call: Biote management will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET on Wednesday, November 8, 2023.To access the conference call by telephone, please dial (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International).To access a live webcast of the call, …biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that ...IRVING, Texas, March 28, 2023--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results ...
Inside Biote Corp.'s 10-K Annual Report: Revenue - Product Highlight. Our ability to raise additional capital through the sale of equity or convertible debt securities could be significantly impacted by the resale of shares of Class A common stock by selling securityholders pursuant to the registration statement on Form S-1 filed with the SEC on …Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 May. 09: CI Certain Restricted Stock Units of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023. Apr. 05: CI Certain Stock Options of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023.BIOTEQUE CORPORATION is a leading medical device manufacturer in Taiwan, specialized in medical disposables for use in hemodialysis access , endovascular ...BioTe Veterinary Laboratories are the experts in microbiology & infectious disease testing. Efficient service, sensible prices, & bespoke panels available.Instagram:https://instagram. nextgen stockdog insurance with no waiting perioddxj etfalgorithmic trading training IRVING, Texas--(BUSINESS WIRE)--May 9, 2023-- Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its (i) 8,397,624 outstanding ...Exhibit 99.1 . Biote Appoints Debby Morris to Board of Directors . IRVING, TX – November 7, 2022 – biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors. down payment for commercial propertyetf kre Following closing of the Business Combination, the common stock and warrants of the combined company, called “biote Corp.,” are expected to commence trading on the Nasdaq Stock Exchange under ... charles mizrahi Biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build, and implement a program desig ned to optimize hormone levels. The Company's Biote Method is a comprehensive, end-to-end practice …Biote Method to be available in IMAC outpatient medical clinics . IRVING, Texas--(BUSINESS WIRE)--Sep. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has entered into a partnership with …